Testing Trametinib and Dabrafenib as a Potential Targeted Treatment in Cancers With BRAF Genetic Changes (MATCH-Subprotocol H)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
GeoVax, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
University of Alabama at Birmingham
National Cancer Institute (NCI)
Weill Medical College of Cornell University
Washington University School of Medicine
Masonic Cancer Center, University of Minnesota
City of Hope Medical Center
Columbia University
Institute of Hematology & Blood Diseases Hospital, China
Thomas Jefferson University
Thomas Jefferson University
Takeda
National Institutes of Health Clinical Center (CC)
Insel Gruppe AG, University Hospital Bern
MitoImmune Therapeutics
National Cancer Institute (NCI)
OHSU Knight Cancer Institute
University of Nebraska
Hospital Universitario Dr. Jose E. Gonzalez
Kyowa Kirin Co., Ltd.
Maastricht University Medical Center
Northside Hospital, Inc.
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Minnesota
National Cancer Institute (NCI)
Masonic Cancer Center, University of Minnesota
University Of Perugia